Table 2.
Number of international units supplied in the first 12 months of the SNTP Program (free of charge) and in the 12 months before to the Program (copayment system)
| Medicines | ATC | Feb. 2010–Jan. 2011 | Feb. 2011–Jan. 2012 | Percentage of charge |
|---|---|---|---|---|
| Medicines included in SNTP Program | ||||
| Regular human insulin | A10AB01 | 1,122,987 | 2,221,324 | 97.8 |
| Isophane insulin (NPH) | A10AC01 | 11,435,131 | 20,352,054 | 78.0 |
| Medicines not included in SNTP Program | ||||
| Single-drug formulations | ||||
| Insulin glulisine | A10AB06 | 429,221 | 575,883 | 34.2 |
| Insulin detemir | A10AE05 | 1,644,945 | 1,864,980 | 13.4 |
| Insulin lispro | A10AC04 | 1,278,932 | 1,396,643 | 9.2 |
| Insulin aspart | A10AB05 | 1,554,705 | 1,696,280 | 9.1 |
| Insulin glargine | A10AE04 | 3,328,109 | 3,533,336 | 9.1 |
| Fixed-dose combinations | ||||
| Regular human insulin + isophane insulin (NPH)a | A10AD30 | 626,589 | 595,233 | −5.0 |
Brazil, February 2010 through January 2012
Adapted from information published [12]
ATC Anatomical therapeutic chemical
a Both drugs are included in the combination SNTP Program at the same concentrations